(Q42463490)

1 November 2017

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth (English)

1 reference

1 November 2017

1 reference

1 reference

Deborah A Altomare

1

1 reference

1 November 2017

Hui Qin Wang

2

1 reference

1 November 2017

Kristine L Skele

3

1 reference

1 November 2017

Assunta De Rienzo

4

1 reference

1 November 2017

Andres J Klein-Szanto

5

1 reference

1 November 2017

Andrew K Godwin

6

1 reference

1 November 2017

Joseph R Testa

7

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

1 November 2017

1 reference

1 November 2017

23

1 reference

1 November 2017

34

1 reference

1 November 2017

5853-5857

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1207721

1 November 2017

0 references

cites work

Frequent activation of AKT2 kinase in human pancreatic carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

The mRNA 5' cap-binding protein eIF4E and control of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

AKT plays a central role in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

7 January 2021

The modular phosphorylation and activation of p70s6k.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

7 January 2021

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

7 January 2021

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

7 January 2021

Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

7 January 2021

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207721

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1207721

1 reference

Dimensions Publication ID

1 November 2017

0 references

1 reference